As I understand, the commercialisation of ArTiMist is significantly derisked given that the formulation is based on an already proven and effective compound - Artemether. So the real question remains is the delivery of this agent in liquid form at least as effective as in tablet form. Hopefully the Phase III trials yield significant results - this should really be investors main concern. The SP will then look after itself. I can't really understand why the SP is still low, given Phase III underway, given Patterson's valuation, etc. Although I guess EMS remains a bit of an unknown. Maybe this is to our advantage now? Bought more at 5.7 yesterday, just hoping for good results.
As I understand, the commercialisation of ArTiMist is...
Add EMS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.2¢ |
Change
-0.003(8.57%) |
Mkt cap ! $3.162M | |||
| Open | High | Low | Value | Volume |
| 3.5¢ | 3.5¢ | 2.9¢ | $91.24K | 2.866M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 216700 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.2¢ | 44447 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
3.0¢ |
Change
-0.003 ( 14.3 %) |
||||
| Open | High | Low | Volume | ||
| 3.4¢ | 3.4¢ | 2.9¢ | 341738 | ||
| Last updated 14.33pm 17/06/2024 ? | |||||
| EMS (ASX) Chart |
